Company Filing History:
1 out of 4,455 
1 out of 78 Years Active: 2015
Title: Sirid-Aimée Kellerman: Innovator in Monoclonal Antibody Development
Introduction
Sirid-Aimée Kellerman, an esteemed inventor based in Menlo Park, CA, has made significant contributions to the field of biotechnology, specifically in developing human monoclonal antibodies. With a focus on innovative solutions to complex biological problems, Kellerman's work has the potential to impact therapeutic modalities for various diseases.
Latest Patents
Kellerman is credited with a patent that pertains to human monoclonal antibodies targeting the activin receptor-like kinase-1 (ALK-1). This invention involves antibodies, including human antibodies and their antigen-binding portions, that bind to the extracellular domain of ALK-1. The patent outlines methods for abrogating the ALK-1/TGF-beta-1/Smad1 signaling pathway. Additionally, it discusses heavy and light chain immunoglobulins derived from these antibodies, the nucleic acid molecules encoding them, and transgenic animals or plants comprising these nucleic acids. This innovative approach not only encompasses methods for creating these antibodies but also highlights the potential applications of the resulting compositions.
Career Highlights
Throughout his career, Sirid-Aimée Kellerman has garnered experience at leading biotechnology firms. Notably, he has worked with Pfizer Corporation and Amgen Fremont Inc., where he collaborated on various projects that align with his expertise in monoclonal antibody development. His unique insights and scientific acumen have contributed to advancements in therapeutic antibodies.
Collaborations
Kellerman has had the privilege of collaborating with talented individuals in the field, including Shelley Sims Belouski and Michael Aidan North. These partnerships have played a crucial role in fostering an environment of innovation and scientific discovery, leading to groundbreaking inventions and developments.
Conclusion
As an accomplished inventor, Sirid-Aimée Kellerman continues to push the boundaries of biotechnology with his pioneering work in monoclonal antibodies, particularly in targeting the ALK-1 pathway. His contributions to the field have not only advanced scientific knowledge but also opened new avenues for therapeutic interventions. With a dedication to innovation and a robust career in biotechnology, Kellerman exemplifies the spirit of invention that drives progress in the medical sciences.